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RESEARCH
PI3K/AKT/mTOR inhibition 
in combination with doxorubicin is an effective 
therapy for leiomyosarcoma
Yael Babichev1†, Leah Kabaroff1†, Alessandro Datti2,3, David Uehling4, Methvin Isaac4, Rima Al‑awar4,5, 
Michael Prakesch4, Ren X. Sun5,6, Paul C. Boutros5,6,7, Rosemarie Venier1, Brendan C. Dickson8 
and Rebecca A. Gladdy1,9,10,11,12*
Abstract 
Background: Leiomyosarcoma (LMS) is a common type of soft tissue sarcoma that responds poorly to standard 
chemotherapy. Thus the goal of this study was to identify novel selective therapies that may be effective in leio‑
myosarcoma by screening cell lines with a small molecule library comprised of 480 kinase inhibitors to functionally 
determine which signalling pathways may be critical for LMS growth.
Methods: LMS cell lines were screened with the OICR kinase library and a cell viability assay was used to identify 
potentially effective compounds. The top 10 % of hits underwent secondary validation to determine their EC50 and 
immunoblots were performed to confirm selective drug action. The efficacy of combination drug therapy with doxo‑
rubicin (Dox) in vitro was analyzed using the Calcusyn program after treatment with one of three dosing schedules: 
concurrent treatment, initial treatment with a selective compound followed by Dox, or initial treatment with Dox 
followed by the selective compound. Single and combination drug therapy were then validated in vivo using LMS 
xenografts.
Results: Compounds that targeted PI3K/AKT/mTOR pathways (52 %) were most effective. EC50s were determined 
to validate these initial hits, and of the 11 confirmed hits, 10 targeted PI3K and/or mTOR pathways with EC50 values 
<1 μM. We therefore examined if BEZ235 and BKM120, two selective compounds in these pathways, would inhibit 
leiomyosarcoma growth in vitro. Immunoblots confirmed on‑target effects of these compounds in the PI3K and/or 
mTOR pathways. We next investigated if there was synergy with these agents and first line chemotherapy doxorubicin 
(Dox), which would allow for earlier introduction into patient care. Only combined treatment of BEZ235 and Dox was 
synergistic in vitro. To validate these findings in pre‑clinical models, leiomyosarcoma xenografts were treated with 
single agent and combination therapy. BEZ235 treated xenografts (n = 8) demonstrated a decrease in tumor volume 
of 42 % whereas combining BEZ235 with Dox (n = 8) decreased tumor volume 68 % compared to vehicle alone.
Conclusions: In summary, this study supports further investigation into the use of PI3K and mTOR inhibitors alone 
and in combination with standard treatment in leiomyosarcoma patients.
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Background
Sarcomas are a diverse group of malignant mesenchymal 
neoplasms with over 50 histologically distinct subtypes 
[1]. They can be broadly classified in two groups: those 
containing simple karyotypic defects including recur-
rent translocations or those with complex cytogenetic 
lesions characterised by multiple altered genes, such as 
leiomyosarcoma (LMS) [1, 2]. LMS accounts for 11 % of 
soft tissue sarcomas (STS) and although its genetic basis 
is not fully characterized, common genetic abnormalities 
include loss of function mutations in p53 or PTEN and 
activating mutations in the PI3K/AKT/mTOR pathways 
[3–6]. Conventional treatment of LMS often involves 
surgical resection, chemotherapy and/or radiation [2]. 
Unfortunately, current 5-year disease specific survival for 
resectable, non-metastatic LMS is 60  % for retroperito-
neal and 75 % in extremity patients [7, 8]. Since the main 
patterns of failure are metastatic disease and multifocal 
local recurrence, effective chemotherapeutic options are 
essential to improve more durable disease control.
First-line LMS chemotherapy currently consists of 
doxorubicin (Dox), an anthracycline that inhibits topoi-
somerase II thereby disrupting DNA repair, in combi-
nation with ifosfamide [9]. However, locally advanced, 
recurrent or metastatic uterine LMS shows only a 25 % 
response rate to Dox when administered at a dose of 
60–80 mg/m2 IV every 3 weeks [10]. The use of Dox in 
cancer therapy is limited by cardiotoxicity, leucopenia, 
thrombocytopenia and the development of resistance 
[10]. Another commonly used regimen is gemcitabine 
(900 mg/m2 day 1 and 8) and docetaxel (100 mg/m2 day 
8), which has response rates ranging from 27 to 53 % in 
uterine and non-uterine leiomyosarcoma [11]. There-
fore, overall poor response rates and significant toxicity 
in LMS patients implores that more effective, less toxic 
selective therapies be developed to improve patient 
outcomes.
In an effort to increase efficacy of treatment, selective 
inhibitors are being widely developed to target tumor-
specific molecular pathways. Recently, STS and other 
solid tumors including breast, lung and colon cancer 
have been characterized as exhibiting PI3K/AKT/mTOR 
dysregulation [12–16]. The PI3K/AKT/mTOR pathways 
are activated by receptor tyrosine kinases (RTK) that 
transmit extracellular signals from the tumor microen-
vironment. These pathways can be dysregulated not only 
by hyperactivation of growth factor signalling but also 
through activating or loss of function mutations affect-
ing key molecules such as AKT and PTEN. Targeting 
these pathways has become a rapidly expanding field in 
drug development as several small molecule inhibitors 
targeting these proteins have recently been studied in 
clinical trials (BKM120, BEZ235 and MK2206) [17–20]. 
However, complex regulation of the PI3K/mTOR path-
ways includes feedback loops allowing targeted proteins 
to be circumvented. Mounting evidence of cross-talk/
redundant functions between pathways MAPK and ERK 
have been linked to the development of adaptive resist-
ance when targeting the PI3K/mTOR pathways [21, 22]. 
Thus, it has been suggested that small molecules target-
ing multiple pathways or combining these agents with 
conventional cytotoxic agents may thwart the develop-
ment of resistance and result in more durable drug ther-
apy [23].
To identify novel selective therapies for LMS that are 
effective and potentially less toxic, we utilized a selec-
tive drug library of 480 small molecule kinase inhibi-
tors. Based on our initial screen with validation studies 
in  vitro, we report the novel finding that PI3K/AKT/
mTOR pathways are functionally important for LMS 
cell survival. Furthermore, we discovered that BEZ235, a 
dual PI3K/mTOR inhibitor, significantly inhibited LMS 
growth in vivo. Finally, this small molecule is synergistic 
with the current standard of care, doxorubicin, suggest-
ing a promising combination therapy for LMS patients.
Methods
Cell line culture conditions and characterisation
Following Research Ethics Board consent at Mount 
Sinai Hospital (Creation of a Sarcoma Cell Line Biore-
pository from Human Tissue MSH REB# 10-0310-C), 
the LMS cell line, STS39, was derived by manual disso-
ciation of a patient sample (pelvic LMS) which was incu-
bated overnight at 37  °C in supplemented DMEM/F-12 
10 % FBS (Life Technologies, Burlington, CA) with 2 μg/
ml collagenase (SigmaAldrich, Oakville, CA). Cells were 
repeatedly aspirated to create single cell suspension, 
centrifuged at 1000 rpm for 5 min, and plated to a T75 
flask. SKLMS1 cells obtained from ATCC were cultured 
in DMEM (Life Technologies), 10  % FBS media. Cells 
were serially passaged with standard conditions and ana-
lysed for copy number variation using array comparative 
genomic hybridization (aCGH) on the Genome-Wide 
Human SNP Array 6.0, and mapped using short tandem 
repeat (STR) analysis (The Centre for Applied Genomics 
(TCAG) Sick Kids, Toronto, CA). Immunocytochemistry 
was performed by staining for desmin [clone DE-U-10] 
(AbCam, Toronto ON, CAN) 1:200, and smooth muscle 
actin (SMA) (clone 1A4) (Dako, Burlington, CA) 1:200, 
mouse IgG (Santa Cruz Biotechnology, Dallas, US) 1:400 
was used to control for background. To ensure the cell 
line was representative of the tumor of origin, immu-
nocytochemistry of STS39 cells was matched to patient 
tumor immunohistochemistry performed by the Depart-
ment of Pathology at Mount Sinai Hospital. Ki67 and 
TUNEL staining were quantitated by ImageJ (148v), while 
Page 3 of 12Babichev et al. J Transl Med  (2016) 14:67 
p-AKTS473 staining was assessed by staining distribu-
tion and intensity. Sequencing of exon 9 and 20 in the 
p85 subunit of PI3K (Ensembl:ENSG00000145675), and 
exon 14 and 15 of mTOR (Ensembl:ENSG00000198793) 
was performed by TCAG.
Kinase library
A 480 compound kinase library was assembled by the 
drug discovery group at the Ontario Institute for Cancer 
Research (OICR). All drugs were used as 100 % solutions 
in DMSO. The drugs encompassed a variety of targets 
including but not limited to PI3K/AKT, EGFR/ErbB2, 
CDKs, and GSK3. BEZ235 and BKM120 were supplied 
by the Medicinal Chemistry Platform or purchased from 
ChemieTek (Indianapolis, US).
Primary screen
A primary drug screen was performed at the SMART 
Facility in the Lunenfeld–Tanenbaum Research Institute 
(LTRI) by seeding SKLMS1 and STS39 cells at a den-
sity of 600 cells/well and 700 cells/well respectively, in 
384 well plates (VWR). Plates were incubated for 6 h to 
ensure cell attachment, at which time drugs were pinned 
at 3 concentrations, 0.2, 1 and 5. Following incubation at 
37  °C for 96 h, 45 μl of AlamarBlue® (LifeTechnologies) 
was added. The fluorescence intensity was then measured 
after 5 h on a BMG Pherastar plate reader. Cells grown 
in 0.1 % dimethylsulfoxide (DMSO) (SigmaAldrich) alone 
served as a control to which the results were normal-
ized, while media with no cells was used for background 
correction.
Drug selection criteria and hit validation
Hits from the primary screen were defined as the top 
10 % of drugs that caused a signal decrease as compared 
to controls across all three dose groups in both cell lines. 
The top 10  % of hits were validated by performing a 
10-point, threefold serial dilution EC50 curve. Stock com-
pounds in the form of lyophilized powder were reconsti-
tuted with DMSO to a concentration of 50 mM. SKLMS1 
and STS39 cells were seeded at a density of 5000 c/well 
and 10,000 c/well respectively, into 96 well plates (Fisher, 
Ottawa, CA) and compounds were added at final con-
centrations ranging from 0.25 nM to 5 μM and incubated 
for 72  h. An ATPlite assay (PerkinElmer) was then per-
formed according to manufacturer’s description and fluo-
rescence read on a PerkinElmer Enspire 2300 multimode 
plate reader. EC50 curves were generated and analysed 
using GraphPad Prism 4.0.
Immunoblots
SKLMS1 and STS39 cells were seeded in six well 
plates at a density of 250,000 c/well and 500,000 c/well 
respectively. Cells were treated with BKM120 or BEZ235 
(5–1000 nM) for 72 h prior to harvest. Following a cold 
PBS (Sigma) rinse, cells were lysed for 20 min on ice with 
RIPA buffer (50 mM pH 7.4 Tris–HCl, 150 mM NaCl, 1 % 
NP-40, 1  mM EDTA) supplemented with phosphatase 
and protease inhibitors (Sigma). Protein concentra-
tion was measured with DC Protein concentration assay 
(BioRad). Electrophoresis was performed using Mini-
Protean TGX gels (Bio-Rad) and transferred to PVDF 
by wet transfer. Immunoblots were performed with the 
following antibodies: p-AKTS473, total AKT, p-S6KT389, 
total S6K, p-4EBP1T37/46, total 4EBP1, PARP-1, all from 
Cell Signaling Technology (Denver, US), and tubulin 
[clone DM1A] (Sigma, St. Louis, USA). All immunoblots 
shown are representative of at least three independent 
experiments.
Combination studies
In vitro combination studies were performed by seed-
ing 96 well plates with SKLMS1 and STS39 cells (5000 
c/well and 10000 c/well respectively). Cells were treated 
with BEZ235 and Dox at multiple concentrations: 
4 × IC50, 2 × IC50, IC50, 0.5 × IC50, 0.25 × IC50 accord-
ing to the following schedule: (1) concurrent treatment 
with Dox and selective inhibitor (SI) for 72 h, (2) SI alone 
for 24 h, followed by Dox for an additional 48 h and (3) 
Dox alone for 24 h followed by SI for an additional 48 h. 
Cell viability was quantified using the ATPlite assay on a 
PerkinElmer Enspire 2300 multimode plate reader and 
analyzed as described below.
Treatment of LMS xenografts with BEZ235 and/or Dox
All in  vivo work was carried out in accordance with 
the Animal Care Committee at the Toronto Centre for 
Phenogenomics, Toronto, Canada. Female NOD.Cg-
PrkdcscidIL2rgtm1Wjl/SzJ mice were purchased from JAX 
Laboratories. At 6–8  weeks of age, animals received an 
intramuscular (i.m.) injection in the right hind limb 
with 5 × 106 SKLMS1 cells. Once palpable, tumors were 
measured with callipers and tumor volumes calculated 
using the following formula: length  ×  width  ×  heigh
t  ×  0.5236 [24]. When tumors reached approximately 
0.5  cm3 (~4–5  weeks for SKLMS1 cell lines), animals 
were assigned to four groups: Group 1. vehicle alone con-
sisting of 10  % NMP (1-methyl-2-pyrrolidone)/PEG300 
90  % daily by oral gavage and biweekly intraperitoneal 
(i.p) injection of PBS, Group 2. BEZ235 alone (25 mg/kg 
of BEZ235 daily by oral gavage dissolved in 10 % NMP/
PEG300 90  % as described previously [25]), Group 3. 
Dox alone (1.2 mg/kg biweekly i.p. injection of Dox dis-
solved in PBS) and Group 4. concurrent treatment of 
BEZ235 and Dox. Body weight and tumor measurements 
were recorded twice a week for the duration of the study 
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(12  days of treatment). Animals were euthanized by 
CO2 asphyxiation when tumors reached approximately 
1.5 cm3 in size.
All tissues were stored either in liquid nitrogen or 10 % 
formalin. Xenograft tumors were stained for desmin 
(Dako), SMA [clone 1A4] (Dako), Ki-67 [clone SP6] 
(ThermoScientific), TUNEL (Roche, TdT) and p-AKTS473 
(Cell Signaling Technology) at 1:100. Immunohistochem-
istry (IHC) was completed using standard protocols. For 
mouse primary antibodies the Mouse-on-Mouse Per-
oxidase Kit (Vector Laboratories, Burlington, ON, CAN) 
was used to prevent false positives to mouse-derived 
antigens.
Statistics
Analysis of drug synergy was performed by calculating 
the combination index (CI) as a measure of interaction 
between two drugs. The CI was calculated according 
to the median- effect principle of the Chou and Talalay 
method using the CalcuSyn software 2.1 (BioSoft, UK) 
[26, 27]. Mann–Whitney test was performed to deter-
mine tumor volume differences between treatment 
groups. Differences of p < 0.05 were considered statisti-
cally significant. One-way ANOVA was performed to 
determine if there was any difference in mouse weight 
between treatment groups.
Results
Kinase inhibitor screen identifies PI3K and/or mTOR 
pathways as promising LMS targets
To identify effective therapies for LMS we screened two 
cell lines with a library of kinase inhibitors (Fig. 1a). Hits 
were defined as the top 10  % of compounds common 
across all dosages in both LMS cell lines (33 compounds). 
Hits were clustered on the basis of their primary kinase 
target (Fig.  1b). Interestingly, we identified a predomi-
nance of compounds that targeted the PI3K/AKT/mTOR 
pathways (52 %), cell cycle regulators (PLK1, CHK1, Wee-
1) (27  %) and other RTK including PDGFR, and FLT3 
(21  %). Overall, 20 (48  %) of the 42 PI3K/AKT/mTOR 
inhibitors included on the OICR plates were considered 
hits. We defined criteria for the selection of promising 
drugs as follows: hits that have nanomolar potency which 
predicts better clinical efficacy and/or compounds in 
phase I/II clinical trials at the time of our study design.
To validate selected hits from the primary screen, we 
retested 20 compounds and determined their EC50 values 
in both cell lines (Fig. 2). More than 70 % of primary hits 
were confirmed (14/20) in at least one cell line and 55 % 
of primary hits were confirmed in both cell lines (11/20). 
Furthermore, of 11 confirmed hits, 10 were molecules 
that targeted the PI3K and/or mTOR pathways, with the 
majority of the EC50 values less than 1 μM (Table 1). Of 
these, we investigated BEZ235 and BKM120 to determine 
their ability to inhibit LMS since both drugs are currently 
under investigation in Phase I/II trials and the low EC50 
values indicate the possibility of a wide therapeutic win-
dow [28, 29]. BEZ235 is a dual ATP-competitive inhibi-
tor for both PI3K and mTOR that demonstrated excellent 
nanomolar range potency (EC50 =  62.8 and 73.5  nM in 
SKLMS1 and STS39, respectively). BKM120 inhibits 
PI3K only and is somewhat less potent (EC50 = 800.0 and 
513.2 nM in SKLMS1 and STS39, respectively).
Selective activity of BEZ235 and BKM120 in PI3K/mTOR 
pathways in LMS cell lines
We next analysed our cell lines to determine if they had 
any common mutations in the PI3K/mTOR axis. Since 
mutations in the p85 subunit of PI3K are a common 
mechanism of PI3K pathway activation in sarcomas [1], 
we sequenced both cell lines but did not identify activat-
ing mutations (data not shown). To determine if LMS 
cell lines were genomically stable with serial passaging, 
aCGH was performed which demonstrated that these cell 
lines were genomically stable over time (Additional file 1: 
Figure S1A). We also performed immunocytochemistry 
Fig. 1 Primary screen with the OICR kinase library for possible novel 
therapies for LMS. a Flow chart detailing experimental procedure.  
b The top 10 % of hits from the primary screen is enriched for inhibi‑
tors targeting the PI3K/AKT/mTOR pathways. Other hits include cell 
cycle regulators, such as PLK1 and Wee‑1, and RTK inhibitors, such as 
PDGFR
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for desmin and SMA to confirm the primary cell line 
STS39 was representative of the original tumor it was 
derived from (Additional file  1: Figure S1B). Further-
more, we assessed endogenous PI3 K and mTOR pathway 
protein levels via immunoblot and found an increased 
level of p110 and p-p85 in SKLMS1 (Additional file  1: 
Figure S1C). RICTOR, a binding partner of mTOR whose 
activity has been implicated in carcinogenesis, was ele-
vated in SKLMS1 consistent with a recent finding in well-
differentiated LMS [30]. Finally, we demonstrated that 
generally protein levels of downstream effectors were 
consistently expressed with serial passaging (Additional 
file 1: Figure S1C).
To determine if the PI3K/AKT/mTOR pathways are 
selectively inhibited in LMS cells, we treated both cell 
lines with BEZ235 or BKM120 for 72 h with five differ-
ent doses (0–1000  nM). Dose–response experiments in 
STS39 and SKLMS1 cell lines demonstrated that BEZ235 
inhibited the phosphorylation of AKTS473, a downstream 
target of PI3K. Inhibition of 4EBP1T37/46, a molecule 
downstream of the mTOR pathway was also observed at 
of 50  nM, however at higher concentrations (>500  nM) 
levels of 4EBP1 were decreased, in particular in SKLMS1 
(Fig.  3). BKM120-treated cells demonstrated decreased 
levels of p-AKTS473 but not p-4EBP1T37/46 at a 500–
1000  nM dose (Fig.  4). These data suggest that BEZ235 
treatment in LMS cells inhibits downstream effectors of 
the PI3K and mTOR pathways and BKM120 treatment 
results in inhibition of PI3K pathway targets in both LMS 
cell lines as expected.
Concurrent treatment with doxorubicin and BEZ235 is 
synergistic in LMS cell lines
Doxorubicin is the first line agent in adjuvant and meta-
static settings in LMS patients [31]. Genetic aberrations in 
the PI3K/AKT pathway are becoming appreciated as com-
mon in STS and more recently in LMS [1, 32, 33]. There-
fore, we tested the efficacy of Dox and PI3K and/or mTOR 
selective inhibitors to determine if combination therapy 
would result in synergy, which may allow for decreased 
drug doses thereby limiting toxicity and perhaps enhanc-
ing overall efficacy of drug therapy in LMS patients.
Fig. 2 Secondary validation of selected hits discovered in primary screen in LMS cell lines. Treatment of SKLMS1 and STS39 cell lines with four 
inhibitors using a 10‑point, threefold serial dilution, generating EC50 curves ranging from 0.25 to 5000 nM. Cells were incubated for 72 h and cell 
viability quantified with ATPlite (n = 3)
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To determine an optimal therapeutic strategy we exam-
ined three dosing schedules: concomitant treatment for 
72  h, or two different sequential treatments (inhibitor 
added 24 h after Dox treatment or Dox added 24 h after 
inhibitor) (Fig. 5a). In order to obtain an effective dosage 
range and dose density, the fixed (or constant) ratio for 
the two drug combination was calculated from the ratio 
of their EC50s data, as described by Chou-Talalay [27]. 
Specifically, BEZ235 and Dox were used at a fixed ratio 
of 1:4 to test for potential synergy and BKM120 and Dox 
were used together at a fixed ratio of 1:1. After the ratio 
was set, the mixture of the two drugs was serially diluted 
and the cells were incubated as per schedules described 
above. Cell viability was analysed with ATPlite.
Combination indexes (CI) were calculated for each 
dose combination. A CI < 1 indicated synergy, a CI = 1 
indicated additive action and a CI > 1 indicated antago-
nism. Synergistic effects were observed with BEZ235 
and Dox in both cell lines across a range of doses with 
median combination indices of 0.62 for SKLMS1 and 
STS39 (Fig.  5b). Synergy was observed during all three 
dosing schedules thus indicating that there is no differ-
ence between the treatment regimens. The combination 
of BKM120 and Dox resulted in an additive effects only 
(range of CI around 1.0) and thus was not pursued fur-
ther in our in vivo studies (Additional file 1: Table S2).
We further investigated the capacity of BEZ235 and Dox 
to inhibit downstream effectors of PI3K/mTOR pathways, 
alone and in combination. Both LMS cell lines were treated 
either with BEZ235 at low (60 nM) or high (500 nM) con-
centrations with or without 500 nM Dox. BEZ235 (60 nM) 
Table 1 EC50 values generated for hits from primary screen
EC50 values generated by the 20 hits found in the primary screen for both STS39 
and SKLMS1. The 10-point dilution curve includes doses ranging from 0.25 to 
5000 nM. Highlighted boxes are inhibitors used in further studies. Inhibitors 
with dash (–) indicate no EC50 value was generated, * indicates a dual inhibitor 
targeting both PI3K and mTOR
Pathway Target Drug EC50 72 h (nM)
SKLMS1 STS39
PI3K/AKT/mTOR PI3K PIK‑75 10.79 14.9
PIK‑90 1705.3 952.2
BKM120 800.0 513.2
ZSTK474 149.0 318.8
PF‑04691502* 59.3 57.0
BEZ235* 62.8 73.5
AKT A‑443654 313.8 430.1
GSK‑690693 – –
MK‑2206 933.5 486.9
mTOR AZD‑8055 12.1 12.61
OSI‑027 – –
Everolimus ‑ –
KU0063794 434.3 240.1
Rapamycin – –
Cell cycle regula‑
tors G2/M
Chk 1 and 2 AZD‑7762 139.9 1001.0
PLK1 BI‑2536 1922.0 –
GSK‑461364 6.7 –
BI‑6727  
(volasertib)
– –
Cell cycle regula‑
tors G1/S
Wee‑1 MK‑1775 40.0 –
Other RTK LIMK LIM2K – –
Fig. 3 BEZ235 inhibits PI3K/mTOR pathway downstream effectors in 
LMS cells. Immunoblot demonstrates decreased levels of p‑AKTS473 
and of p‑4EBP1T37/46 in total lysates from SKLMS1 and STS39 cells 
treated with BEZ235 for 72 h at concentrations ranging from 0 to 
1000 nM/L. Total AKT, 4EBP1 and tubulin levels demonstrate equal 
loading of protein lysates
Fig. 4 BKM120 inhibits PI3K but not mTOR pathway downstream 
effectors in LMS cells. Immunoblot demonstrating decreased levels of 
p‑AKTS473, but not in p‑4EBP1T37/46 in total lysates from SKLMS1 and 
STS39 cells treated with BKM120. SKLMS1 cells were treated for 72 h 
at concentrations ranging from 0 to 1000 nM/L. Total AKT, 4EBP1 and 
tubulin levels are shown for loading control
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alone and in combination with Dox was able to inhibit 
phosphorylation of 4EBP1T37/46 in SKLMS1 cells (Fig. 5c). 
Treatment of STS39 cells with BEZ235 at 60 nM caused a 
reduction in phosphorylation of AKTS473, with no change 
in the downstream effector p-4EBP1T37/46. As expected, 
increasing the dosage of BEZ235 to 500  nM dramatically 
decreased phosphorylation of AKTS473 and abolished the 
phosphorylation of 4EBP1T37/46. This effect was augmented 
with the addition of Dox. Thus, combination treatment 
causes decreased phosphorylation level of PI3K/mTOR 
downstream effectors in contrast to single Dox or BEZ235 
treatment, reinforcing selective inhibition of these path-
ways, which warranted in vivo confirmation (Fig. 5c).
BEZ235‑Dox combination therapy induces cell death 
via apoptosis in vitro
To determine whether cell death following BEZ235 treat-
ment was due to apoptosis, we evaluated Annexin V 
binding to the surface of drug-treated LMS cells with 
flow cytometry (Additional file  1: Figure S2). Annexin 
V-positive, 7-AAD-negative cells representative of early 
apoptotic cells and AnnexinV-positive, 7-AAD-positive 
cells indicative of late apoptotic cells were both present 
at low levels in cells treated with a single agent BEZ235 or 
Dox for 72 h (range 0.5–3.1 % of apoptotic cells). This cell 
population was increased with BEZ235 and Dox com-
bination treatment for 72 h (15.3 and 9.6 % respectively 
for early and late apoptotic cells in SKLMS1, p < 0.01; 8 
and 8.2 % respectively for early and late apoptotic cells in 
STS39, p < 0.01) suggesting that combination treatment 
may inhibit LMS survival via apoptosis. Furthermore, 
PARP-1 levels, a marker of apoptosis, were increased at 
concentrations of 500 nM BEZ235 and with BEZ235 and 
Dox combination treatment as compared to controls by 
immunoblot (data not shown).
Concurrent treatment with doxorubicin and BEZ235 
inhibits tumor growth in vivo
We next sought to determine if Dox and BEZ235 have 
synergistic effects in vivo. Thus, SKLMS1 cell lines were 
injected i.m. to recapitulate the microenvironment that is 
common in LMS formation. NSG mice bearing palpable 
tumors were randomized into 4 groups to receive vehicle, 
BEZ235, Dox, or a combination of both drugs. BEZ235 
was administered for 12 days at 25 mg/kg po daily, which 
is a dose and schedule that have been shown to be effi-
cacious for other in vivo cancer models [25]. Doxorubicin 
was given 1.2 mg/kg bi-weekly, i.p., which would achieve 
plasma levels comparable to human dosing [34, 35]. 
Treatment was well tolerated and body weight loss was 
<10 % of baseline in all treatment groups over the study 
period (Fig. 6a). Overall, tumor growth was inhibited by 
50  % following administration of BEZ235 alone, which 
was further reduced by 71  % by combination therapy 
compared to vehicle only (Fig.  6b). Pathologically, both 
untreated and treated tumors were well demarcated, and 
comprised of spindle cells with eosinophilic cytoplasm 
and a fascicular pattern. The nuclei were ovoid and elon-
gated with mild to moderate pleomorphism and brisk 
mitotic activity was seen in all cases (Fig. 6c). The tumour 
morphology and immunophenotype of the xenograft 
tumors was classified as LMS. No difference was observed 
in either Ki67 or TUNEL staining, markers of prolifera-
tion and apoptosis respectively, between the study groups 
(Fig.  6c and data not shown) in contrast to our in  vitro 
data. Treatment with BEZ235 alone or in combination 
with Dox showed decreased in p-AKTS473 levels when 
compared with vehicle and Dox controls (Fig. 6c). Thus, 
dual treatment Dox and BEZ235 is more effective in 
inhibiting LMS tumor growth in vivo compared to single 
agent therapy. Although expression of proliferation and 
apoptosis were not statistically significant, in vivo regula-
tion of AKT appeared to differ between treatment groups 
based on pAKT staining (Fig. 6c).
Discussion
Advances in the development of selective therapeutic 
agents have resulted in exciting changes to the thera-
peutic landscape for solid tumors; however, success in 
treating sarcoma patients has remained limited. Activa-
tion of the PI3K/AKT/mTOR pathways through different 
mechanisms including activation of IGFR or PI3K, loss of 
PTEN, RICTOR amplification and/or increased p-AKT 
has been reported in LMS and other sarcoma subtypes 
[1, 36]. Recent clinical trials with selective PI3K and/or 
mTOR inhibitors have reported favourable efficacy and 
acceptable toxicity in solid tumors [37, 38].
Kinase inhibitor screen identifies PI3K/AKT/mTOR 
inhibitors as potential therapeutic targets in LMS
In this pre-clinical study, we screened a collection of 480 
kinase inhibitors using two LMS cell lines, one patient-
derived and the other commercially available. Both cell 
lines were morphologically and immunophenotypically 
compatible with LMS and formed xenografts in  vivo, 
thereby validating this LMS model system. Eleven poten-
tial hits were identified in our primary screen; with 10 out 
of 11 molecules targeting the PI3K and/or mTOR path-
ways (Table 1). Although several compounds matched the 
potency criteria, they were excluded from further analy-
sis in this study because of poor performance in clinical 
trials. Therefore, two compounds that showed favourable 
selectivity profiles and were in clinical trials at the time 
of our study initiation, BEZ235 (a dual PI3K and mTOR 
inhibitor) and BKM120 (PI3K inhibitor) were chosen for 
further assessment. BEZ235 and BKM120 have shown 
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Fig. 5 Combination studies of BEZ235 and Dox demonstrate synergy in LMS cell lines in vitro. a Dose schedule used in combination treatment. 
Three treatment schedules were investigated: schedule 1—concurrent treatment for 72 h, schedule 2—single agent therapy with inhibitor for the 
first 24 h followed by concurrent Dox treatment for the next 48 h and schedule 3—single agent Dox treatment for the first 24 h followed by concur‑
rent treatment with the inhibitor for 48 h. b Combination index (CI) graphs resulting from the treatment of SKLMS1 cells with BEZ235 or BKM120 
and Dox following 3 dosing schedules to determine optimal treatment regime. Viability was determined using ATPlite and analysed using CalcuSyn 
software. Treatment with BEZ235 (15–240 nM) and Dox (125–2000 nM) showed synergy in all 3 schedules (CI < 0.9), while combination BKM120 and 
Dox treatment was not synergistic in any of the treatment schedules (n = 3). For detailed CI ranges see Additional file 1: Table S2. c Immunoblot 
demonstrates decrease in p‑AKTS473, and p‑4EBP1T37/46 levels in total lysates from STS39 cells treated with BEZ235 for 72 h at the indicated concen‑
trations and in combination with Dox. Total AKT, 4EBP1 and tubulin levels are shown as the loading controls
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efficacy in many types of cancer, such as breast can-
cer with activating PI3K mutations [39], ovarian cancer 
[40], pancreatic cancer [41], rhabdomyosarcoma [42, 43], 
hepatocellular carcinoma [44], undifferentiated pleo-
morphic sarcoma (UPS) in cell lines and/or animal mod-
els [45]. Although BEZ235 is no longer being marketed 
the field of development for PI3K/mTOR inhibitors (i.e. 
BYL719, PF-05212384; http://www.clinicaltrials.gov) is 
expanding clinically.
Dysregulated PI3K/AKT/mTOR signalling has been 
implicated in tumor progression and metastasis in mul-
tiple cancers of epithelial origin [46] and recent data has 
begun to elucidate that these signalling pathways may 
be critical in STS. Specifically, in a mouse model where 
PTEN, a known tumor suppressor, was inactivated using 
a conditional smooth muscle promoter, AKT activity 
played a critical role in smooth muscle transformation 
and LMS development [5]. Also zebrafish expressing 
Fig. 6 BEZ235/Dox combination inhibits LMS tumor growth in vivo. a Body weight is not significantly altered over the course of the experiment 
following administration of drugs in any treatment group (p = ns); b Box plots depict median tumor volume at experimental endpoint (after 12 days 
drug treatment), where vehicle (n = 6) had a median of 991.3 ± 236.0 mm3, while BEZ235 (n = 7), Dox (n = 7) and BEZ235/Dox (n = 6) groups had 
median volume of 498.3 ± 149.0, 836.6 ± 179.8, 286.7 ± 125.6 mm3 respectively (*p < 0.05 comparing treatment groups to vehicle, #p < 0.05 com‑
paring BEZ235 treatment group with dual agent treatment group); c Representative photomicrographs demonstrating tumor morphology (H and 
E), cell proliferation (Ki‑67), and p‑AKTS473 status after treatment with BEZ235 or the combination of BEZ235 and Dox in SKLMS1 tumor xenograft 
specimens. All photomicrographs are 100× magnification
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constitutively active AKTSer473 in mesenchymal progeni-
tors resulted in the development of well-differentiated 
liposarcoma [32]. Furthermore, mutations in the PI3K 
receptor are frequently seen in myxoid round cell liposar-
coma [1]. Finally, in a detailed pathologic assessment of 
human LMS RICTOR, a major component of the mTOR2 
complex was significantly overexpressed [29].
PI3K/mTOR pathway inhibition enhances 
doxorubicin‑induced cell death in LMS
Doxorubicin is a potent anticancer drug used to treat 
several solid tumors including sarcoma. Despite being 
the primary treatment used for LMS, Dox has only par-
tial efficacy, and its cardiotoxicity is a limiting factor. 
Furthermore, development of drug resistance to Dox is 
a major challenge undermining successful cancer treat-
ment [10]. Dox has been shown to cause activation of 
AKT before apoptosis onset in cells [47]. This early 
induction of AKT may help confer chemotherapeutic 
resistance against Dox and provide a window in which 
to treat with PI3K/AKT inhibitors. Therefore, treatment 
of LMS by the combinations of PI3K/mTOR inhibitors 
with conventional chemotherapy agents may be benefi-
cial, increasing the efficacy of Dox and thereby possibly 
improving the success of combination therapy in LMS 
patients.
Thus, we investigated whether combination of Dox and 
PI3K/mTOR inhibitors would have synergistic effects 
on LMS growth in  vitro. Furthermore, we investigated 
whether these drug combinations should be administered 
concomitantly or sequentially by evaluating 3 treatment 
regimens: cells pre-treated with either drug, or concur-
rent treatment. CI results indicated that the anti-prolif-
erative effect of the combination of BEZ235 and Dox was 
synergistic in both LMS cell lines at all dose levels tested. 
However, the treatment of LMS cells with the combina-
tion of BKM120 and Dox did not result in synergy. Based 
upon these results, in vivo experiments were performed 
using only the BEZ235 and Dox combination in an intra-
muscular xenograft model of LMS. Although single agent 
Dox did not significantly inhibit tumor growth compared 
to control animals, administration of BEZ235 alone or in 
combination with Dox resulted in significant reduction in 
tumor volume. Our findings are similar to reports from 
Kirsch et al. who showed a response rate of 11.1 % after 
BEZ235 treatment which increased to 50 % upon combi-
nation with Dox when treating another common sarcoma 
subtype UPS [45]. I.
Conclusions
In summary, we demonstrate that inhibition of the PI3K 
and mTOR pathways impairs LMS growth in  vitro and 
in vivo. Also, we describe that the use of PI3K and mTOR 
inhibitors may have a synergistic effect with doxorubicin, 
standard chemotherapy for this disease. Thus, future 
studies with inhibitors targeting these pathways are 
warranted.
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